Reducing burden of disease in gMG: Exploring the role of FcRn inhibitors
touchPANEL DISCUSSION for touchNEUROLOGY
Listen to two expert neurologists and a neurology nurse as they explore the role of neonatal Fc receptor (FcRn) inhibitors in improving the burden of disease in patients with generalized myasthenia gravis. The faculty will consider how the burden of disease and treatment in patients with generalized myasthenia gravis can be used to inform treatment decisions, the latest clinical data for FcRn inhibitors and the best practice strategies for using FcRn inhibitors in clinical practice.
The experts
Prof. Michael Nicolle – Western University and London…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.